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Introduction: Chronic obstructive pulmonary disease (COPD) is a major public health problem. 
It imparts a substantial economic burden on individuals and society. Acute exacerbations are the 
main cause of hospital admissions and hospitalizations in patients with COPD in Turkey.
Objectives: We aimed to determine the costs of hospitalization in patients with acute 
exacerbations of COPD (AECOPD).
Results: A total of 7832 (1556 women, 6276 men) patients were hospitalized due to acute 
exacerbations of COPD between 2005–2009 in the Samsun Chest Diseases and Thoracic Surgery 
Hospital, northern Turkey. The mean age was 64.6 ± 19.8 years old and median length of hos-
pital stay was 14.8 ± 9.5 days. The mean cost per admission was US$718 ± 364. Drug costs 
accounted for the largest portion (53.5%) of the mean cost, followed by bed cost (19.6%). One 
hundred seventy-four (2.2%) of the total hospitalized patients with AECOPD died in hospital.
Conclusion: AECOPD continues to have both significant economic burden and high mortal-
ity rate.
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Introduction
Although chronic obstructive pulmonary disease (COPD) is a preventable and treatable 
disease, it remains a significant public health problem. COPD is a major chronic cause 
of mortality and morbidity and it has been identified as the fourth leading cause of 
mortality and morbidity. Unlike many leading causes of death and disability, COPD 
is projected to increase in much of the world as smoking habits rise and the population 
ages.1,2 It was estimated by the World Health Organization (WHO) in 2000 that 
274 million people worldwide died of COPD.3 Acute exacerbation is the main cause 
of hospitalization in patients with COPD. The number of patients hospitalized for 
acute exacerbation of COPD (AECOPD) accounts for 13% of all admitted patients.4 It 
imparts a substantial economic burden on individuals and society. Hospitalization for 
acute exacerbations represents a major component of the socioeconomic burden related 
to COPD.5 Hilleman et al reported that hospitalization costs represent 40.4% of total 
health care costs for patients with mild COPD, and 62.6% of total costs for patients 
with severe COPD.6 Very few studies have quantified the economic and premature 
mortality associated with COPD. The aim of this study was to determinate the costs 
of hospitalization in patients with AECOPD.
Material and methods
Samsun is the biggest city in the Black Sea region of Turkey. Samsun Chest Diseases 





surgery in northern Turkey. More than 100,000 patients with 
respiratory problems are referred to the hospital per year. 
Diagnosis of AECOPD (emphysema and/or chronic bronchitis) 
was based on the presence of any combination of the follow-
ing symptoms: increased dyspnea and increased production 
and purulence of sputum that led to a change or increase in 
treatment. This study aimed to investigate the costs in hospi-
talized patients with AECOPD. Data on AECOPD manage-
ment were retrospectively taken and evaluated directly from 
the medical records. Costs in this analysis were identified 
for drugs (including short-acting and long-acting β-agonists, 
ipratrobium, theophylline, inhaled and oral steroids, and anti-
biotics), oxygen therapy, non invasive mechanical ventilation, 
emergency department visit, laboratory tests, diagnostic tests, 
and hospitalizations. The Institutional Review Board approved 
the use of medical records. As a state hospital, all expenditure 
was at prices set by the state. Expenditure was calculated in 
US dollars (exchange rate at the time of the study, 1.5 Turkish 
liras per US dollar).
Results
The results of the study and characteristics of patients are 
presented in Table 1. A total of 60,529 patients with COPD 
were seen in the Samsun Chest Diseases and Thoracic 
Surgery Hospital. 7832 (12.9%) patients were hospitalized 
due to mild and moderate AECOPD; 19.8% of patients 
were women (n = 1556) and 80.1% of patients were men 
(n = 6276). The mean age of patients was 64.6 ± 19.8 years. 
The median length of hospital stay was 14.8 ± 9.5 days. 
The numbers of patients hospitalized per year were 1061, 
1952, 1794, 1144, and 1181 in 2005, 2006, 2007, 2008, and 
2009, respectively. The mean hospital costs per admission 
were $668 in 2005, $765 in 2006, $768 in 2007, $667 in 
2008, and $682 in 2009. The mean cost of hospitalization 
over 5 years was $718 ± 364/per admision. The percentages 
of mean costs are demonstrated in Figure 1. Drug costs 
were the highest (53.5%) followed by bed cost (19.6%), 
laboratory (9.8%), radiology (6.2%), examination (4.6%) 
and emergency department costs (3.9%), and other (nonin-
vasive ie, ventilation) costs (2.4%). Of the total hospitalized 
patients with AECOPD, 174 (2.2%) patients died in hospital. 
Progressive respiratory failure, lung cancer, pulmonary 
infections, and cardiovascular comorbidities were major 
causes of death in hospitalized patients with AECOPD.
Discussion
COPD is a major public health problem. It is a costly 
disease with both direct costs (value of health care 
resources devoted to diagnosis and medical management) 
and indirect costs (monetary consequences of disability, 
missed work, premature mortality, and caregiver or family 
costs resulting from the illness). According to reported 
articles, hospital admission rates are suitable for detect-
ing the health burden of COPD.4,7 Acute exacerbations are 
the main cause of hospitalization in patients with COPD. 
Hospitalization-related costs are the largest portion of all 
expenditure for patients with COPD. Hospitalization costs 
Table 1 Characteristics of patients
Characteristics n (%)
Total number of COPD patients 60529
hospitalized COPD patients 7832 (12.9)
Premature mortality  174 (2.2)
Age (mean ± sD years) 64.6 ± 19.8
Male 6276 (80.1)
Female 1556 (19.8)
Costs by year (Us$)
  2005 $668
  2006 $765
  2007 $768
  2008 $667
  2009 $682
Mean cost (Us$) $718 ± 364
Distribution of costs 
  Drug 53.5%
  Bed 19.6%
  Laboratory 9.8%
  Radiology 6.2%
  Examination 4.6%
  Emergency department 3.9%
  Other 2.4%















Figure 1 Distribution of mean costs (2005–2009) acute exacerbation of chronic 
obstructive pulmonary disease.





represent between 40% and 57% of total direct costs gener-
ated by patients with COPD.5,9–12 The exacerbations account 
for 35%–45% of the total per capita health care costs for 
COPD.4 Hilleman et al reported that the hospitalization 
costs of patients with mild, moderate, and severe COPD 
were $680, $2,658, and $6770, respectively.6 Recent studies 
showed that there are variable differences in mean costs of 
AECOPD between countries. The cost of hospitalization 
for COPD was calculated to be $7,100 in United States 
and $2,652 in Spain. The mean costs of our study were 
lower than those of other studies.9 Miravitlles et al noted 
the mean cost of AECOPD was $239.7 for hospitalization 
for 15 days.4 In our study, the mean cost of hospitalization 
due to AECOPD per admission was $718 ± 364 between 
2005 and 2009. The median length of hospital stay was 
14.8 ± 9.5 days. The reported studies presented different 
percentages of costs. According to one article in Spain, 
reported the highest cost was hospitalization (58%) and 
drug acquisition was 32.2%.10 In China, the highest abso-
lute cost was drug cost (71.2%), followed by laboratory cost 
(16.7%), and bed cost was the lowest cost (4.1%).14 In the 
present study, the percentage of drug cost was the highest 
(53.5%), followed by bed cost (19.6%). We know that the 
different costs are related to the differences in reference 
prices (drugs, laboratory), management practices, and 
health care systems.4 In Turkey, the bed cost is lower, but 
drug prices are higher than in other European countries. 
Furthermore, the mean cost of this study was lower than 
reported studies because patients who needed the intensive 
care unit (ICU) were not included in this study.
Nurmagambetov et al reported the estimated COPD-
related total medical costs per patient decreased 22% 
largely with a decrease in the cost of hospitalizations 
for COPD.15 Although many investigatons have found 
inpatient mortality rates associated with COPD exacerba-
tions to be between 2.5% and 4%, GOLD has reported an 
overall rate of 10%, which increases to 40% in 1 year.18,19 
  Groenewegen et al reported the mortality rate during hos-
pital stay was 8%.8 We detected a premature mortality rate 
during hospitalization of 2.2% in patients with AECOPD. 
Our result was lower than in other studies because the 
patients who needed intensive care were not included 
this study. (the patients who needed intensive care were 
referred to the university hospital). In the present study, 
progressive respiratory failure, lung cancer, pulmonary 
infections, and cardiovascular comorbidities appear to 
be major causes of death in hospitalized patients. Other 
studies reported in-hospital mortality rates 11%–24%.7,16,17 
In these studies, the high mortality rates were caused by 
mechanical ventilation and ICU.
In conclusion, acute exacerbations of COPD continues 
to have both significant economic burden and high mortality 
rate.
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